March 22 (Reuters) - GlaxoSmithKline PLC:
* Statement on new information relating to manufacture of rotarix (rotavirus
vaccine)
* Says is now reviewing how best to replace the cell bank and virus seeds used
as base production material
* Says will continue to manufacture rotarix
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Statement on new information relating to manufacture of rotarix (rotavirus
vaccine)
* Says is now reviewing how best to replace the cell bank and virus seeds used
as base production material
* Says will continue to manufacture rotarix
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
